Top Banner
Pregnancy & Newborn Screening Developments Medium Chain Acyl CoA Dehydrogenase Deficiency (MCADD)
13

Pregnancy & Newborn Screening Developments Medium Chain Acyl CoA Dehydrogenase Deficiency (MCADD)

Jan 11, 2016

Download

Documents

Pierce Wells
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 5: Pregnancy & Newborn Screening Developments Medium Chain Acyl CoA Dehydrogenase Deficiency (MCADD)

Complications of MCADD

• Because fat fuels cannot be used, these patients quickly use up glucose and may develop hypoglycaemia

• High levels of partially broken down fatty acids and low blood glucose concentrations causes the patient to become drowsy, comatosed and eventually stop breathing

• Short term effects: seizures, cardiac arrest, coma, sudden death

• Long term effects: developmental and behavioural disabilities, failure to thrive, cerebral palsy and attention deficit disorder

• 1 in 4 infants die at 1st presentation before diagnosis made

Page 7: Pregnancy & Newborn Screening Developments Medium Chain Acyl CoA Dehydrogenase Deficiency (MCADD)

How is MCADD managed?

• Scottish National Screening Laboratory notify Regional Metabolic Team (RMT) in Glasgow or Edinburgh

• RMT contacts family by telephone to give screening result and follow up plan

• RMT informs MCADD Designated Team (MDT)*• Provide MDT and/or GP, HV or midwife with MCADD resource pack• Arrange face-to-face consultation by member of MCADD

Designated Team and/or GP, HV or midwife as per local protocol• Arrange follow up visit with MCADD Designated Team within 24

hours or as soon as practically possible

*MDT may be same as the RMT for some NHS Boards